Full Press Release Details
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline.
IMMP
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
Key Takeaway: Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
Price reaction · baseline $3.75 (2021-08-27 close) · 4 other IMMP headline(s) in the window, move may be shared
day 0 close · peak
-1.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)